New York A 9248: Requires pharmaceutical drug manufacturers and wholesalers to annually disclose all gifts to certain health care practitioners

Bill Text

Bill Search and Legislative Information | New York State Assembly 

• 

• 

• 

• 

• 

• 

• 

• 

 Skip to main content 

 New York State Assembly

 Speaker Carl E. Heastie

 --> 
 --> 

 --> 

• 
 Assembly Members 

• 
 Legislative Info 

• 
 Public Hearings 

• 
 Speaker's Press 

• 
 Assembly Reports 

• 
 Committees & More 

• Bill Search Home
• Laws
• Legislative Calendar
• Public Hearing Schedule
• Assembly Calendars
• Assembly Committee Agenda 

 Javascript must be enabled to properly view this page. 

 Bill No.: 

• Summary 
• Actions 
• Committee&nbspVotes 
• Floor&nbspVotes 
• Memo 
• Text 
• LFIN 
• Chamber&nbspVideo/Transcript 
A09248 Summary:

BILL NOA09248 

&nbsp

SAME ASNo Same As

&nbsp

SPONSORDiPietro

&nbsp

COSPNSR

&nbsp

MLTSPNSR

&nbsp

Add Art 2 Title 3-A §§245 - 245-e, Pub Health L

&nbsp

Enacts the New York state pharmaceutical drug manufacturer and wholesaler disclosure act; requires pharmaceutical drug manufacturers and wholesalers to annually report to the New York department of health, for disclosure to the general public, all of its gifts to health care practitioners that prescribe drugs when such gifts have a value of seventy-five dollars or more; authorizes the commissioner of health to impose penalties and promulgate necessary rules and regulations.

Go to top A09248 Actions:

BILL NOA09248 

&nbsp

11/07/2025referred to health

01/07/2026referred to health

Go to topA09248 Committee&nbspVotes:

Go to topA09248 Floor&nbspVotes:

There are no Assembly votes for this bill in this legislative session.

Go to topA09248 Text:

 STATE OF NEW YORK
 ________________________________________________________________________

 9248

 2025-2026 Regular Sessions

 IN ASSEMBLY

 November 7, 2025
 ___________

 Introduced by M. of A. DiPIETRO -- read once and referred to the Commit-
 tee on Health

 AN ACT to amend the public health law, in relation to disclosure of
 certain gifts provided by drug manufacturers or wholesalers to health
 care providers

 The People of the State of New York, represented in Senate and Assem-
 bly, do enact as follows:

 1 Section 1. Article 2 of the public health law is amended by adding a
 2 new title 3-A to read as follows:

 3 TITLE III-A
 4 NEW YORK STATE PHARMACEUTICAL DRUG MANUFACTURER AND
 5 WHOLESALER DISCLOSURE ACT
 6 Section 245. Legislative intent.
 7 245-a. Definitions.
 8 245-b. Disclosure requirements.
 9 245-c. Annual consumer guide on pharmaceutical drug manufacturer
 10 and wholesaler gifts to health care providers.
 11 245-d. Penalties.
 12 245-e. Rules and regulations.
 13 § 245. Legislative intent. The legislature finds that the cost of
 14 prescription drugs in the United States has grown dramatically. Accord-
 15 ing to the Centers for Disease Control, spending on retail prescription
 16 drugs in the United States more than tripled from fifteen billion
 17 dollars in nineteen hundred eighty-two to forty-eight billion two
 18 hundred million dollars in nineteen hundred ninety-two, then more than
 19 tripled again to one hundred sixty-two billion four hundred million
 20 dollars in two thousand two. In per capita terms, retail prescription
 21 drugs spending increased from sixty-four dollars in nineteen hundred
 22 eighty-two to five hundred sixty-nine dollars in two thousand two. In
 23 two thousand five, spending on pharmaceuticals rose to two hundred

 EXPLANATION--Matter in italics (underscored) is new; matter in brackets
 [ ] is old law to be omitted.
 LBD13456-01-5

 A. 9248 2

 1 fifty-one billion eight hundred million dollars. While the availability
 2 of useful new drugs to treat chronic conditions such as heart disease,
 3 hypertension and depression accounts for much of the increased spending,
 4 there is widespread concern about the impact aggressive marketing by
 5 drug manufacturers and wholesalers has had on drug costs and prescribing
 6 patterns. In addition to the explosive growth in direct-to-consumer
 7 advertising, these marketing efforts are often directed at health care
 8 providers and include gifts, paraphernalia, trips and travel, food and
 9 entertainment. A Competitive Media Reporting Study found that drug
 10 companies provided seven billion two hundred million dollars worth of
 11 free samples to physicians' offices in nineteen hundred ninety-nine. The
 12 drug industry sponsored more than three hundred fourteen thousand physi-
 13 cian "events" in two thousand one, ranging from catered lunches in
 14 hospital conference rooms to weekend getaways at resorts, nearly double
 15 the number four years earlier. Drug companies spent some twenty-two
 16 billion dollars in marketing in two thousand three. According to the
 17 Journal of the American Medical Association, ninety percent of drug
 18 company marketing is directed at physicians. Esteemed medical publica-
 19 tions such as the Journal of the American Medical Association and the
 20 British Medical Journal produced studies that suggest these mar